Over the past two decades, diagnostic applications have become elementary for in-depth studies on the development of global public health. Traditionally, laboratory diagnostic tools are used for the detection of diseases. Even though they still play a key role in the diagnosis of diseases, point-of-care testing (POCT) performed near the patient or by the patient himself has become more and more commonplace in recent years. Especially in such cases that require immediate treatment, such as acute myocardial infarction or diabetes monitoring, the rapid confirmation of a clinical finding is essential. Hence, there is a growing need for POCT devices that can be operated by non-experts and that are concurrently capable of performing precise in vitro diagnostic tests in a short time1,2,3,4.
Remarkable improvements have already been achieved in the field of POCT. However, there are still many challenges to overcome5,6,7,8. For a POCT platform to be successfully launched to the market and to be competitive with laboratory diagnostics, the device must strictly fulfill the following requirements: (i) provide precise and quantitative test results that are consistent with laboratory findings; (ii) have short sample-to-result times, enabling the immediate treatment of the patient; (iii) feature uncomplicated and easy handling, even when operated by untrained individuals, and require minimized user intervention; and (iv) comprise of a low-cost sensor unit designed for single-use applications. Furthermore, equipment-free diagnostics are favorable, mainly in resource-poor environments3,4,6.
Due to these severe requirements, only two POCT systems based on electrochemical detection (e.g., blood glucose test strips) and on lateral flow immunoassays (e.g., home pregnancy tests) have been successfully launched to the market so far. However, both systems suffer from disadvantages such as poor performance (i.e., blood glucose monitoring has inaccurate test results and lateral flow assays only provide qualitative (positive or negative) measurement results)4,6. These drawbacks of conventional POCT systems have led to an increasing demand on exploring new technologies that offer fast, low-cost, and quantitative detection at the point of care4,5.
To meet these challenges facing POCT devices, DFR technology has been recently employed for the fabrication of disposable and low-cost biosensors9,10,11,12,13,14. Compared to soft and liquid lithographic materials, such as PDMS or SU-8, DFRs present many benefits: they (i) are available in a variety of compositions and thicknesses (from a few microns to several millimeters); (ii) have a very rough surface area, which facilitates adhesion to various materials; (iii) feature excellent thickness uniformity; (iv) offer cheap, facile, and high-throughput fabrication for mass production; (v) are easy to cut with various low-cost tools, like a simple pair of scissors; and (vi) allow for the creation of three-dimensional structures, such as microfluidic channels, by stacking multiple DFR layers on top of each other.
On the other hand, DFRs in general have a relatively poor resolution compared to liquid photoresists, which is mainly caused by the film thickness and by the increased distance between the mask and the DFR due to the protective foil, which additionally enables light scattering. Still, for the manufacturing of integrated microfluidic biosensors, DFRs are highly suitable for low-cost mass production.
Therefore, we present in this work the fabrication and application of a DFR-based electrochemical microfluidic biosensor. The detailed protocol describes each production step of the biosensor platform, the on-chip immobilization of a DNA-based model assay, and its electrochemical readout using the stop-flow technique. This universal platform enables the detection of numerous kinds of biomolecules, using different assay technologies (e.g., genomics, cellomics, and proteomics) or assay formats (e.g., competitive, sandwich, or direct). Based on such a DFR platform, our group previously successfully demonstrated the rapid and sensitive quantification of various analytes, including antibiotics13,15,16 (tetracycline, pristinamycin, and ß-lactam antibiotics), troponin I17, and substance P18.